Valuation: Repligen Corporation

Capitalization 9.48B 8.12B 7.56B 7.04B 13.15B 854B 14.13B 86.68B 34.19B 409B 35.55B 34.81B 1,498B P/E ratio 2025 *
197x
P/E ratio 2026 * 146x
Enterprise value 9.2B 7.89B 7.34B 6.83B 12.77B 829B 13.71B 84.12B 33.18B 397B 34.5B 33.78B 1,454B EV / Sales 2025 *
12.5x
EV / Sales 2026 * 11x
Free-Float
93.44%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.95%
1 week-0.61%
Current month+2.77%
1 month+7.00%
3 months+13.27%
6 months+38.80%
Current year+2.77%
More quotes
1 week 164.19
Extreme 164.19
175.77
1 month 156.01
Extreme 156.01
175.77
Current year 162.21
Extreme 162.2101
175.77
1 year 102.96
Extreme 102.965
182.52
3 years 102.96
Extreme 102.965
211.13
5 years 102.96
Extreme 102.965
327.32
10 years 20.07
Extreme 20.07
327.32
More quotes
Manager TitleAgeSince
Chief Executive Officer 56 2024-08-31
Director of Finance/CFO 52 2023-09-24
Chief Operating Officer 63 2020-02-29
Director TitleAgeSince
Chairman 74 2011-12-13
Chairman 62 2024-08-31
Director/Board Member 60 2014-06-11
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.95%-0.61%+6.29%-5.22% 9.39B
-1.02%+0.36%+10.98%+10.15% 219B
-0.59%+0.94%+20.20%+20.70% 125B
+1.93%+0.97%+44.87%+106.88% 65.12B
-0.00%+4.00%-13.24%-20.85% 57.77B
-0.24%+5.51%+22.53%+87.40% 53.45B
+5.43%+9.54% - - 33.72B
+5.31%+4.92%-11.10%-33.75% 26.29B
+1.54%+4.29%+26.75%+29.94% 25.21B
+0.33%+0.28%+5.50%-32.18% 24.25B
Average +0.98%+1.97%+12.53%+18.12% 63.92B
Weighted average by Cap. +0.70%+1.78%+14.64%+23.58%
See all sector performances

Financials

2025 *2026 *
Net sales 733M 628M 585M 544M 1.02B 66.05B 1.09B 6.7B 2.64B 31.61B 2.75B 2.69B 116B 824M 706M 657M 612M 1.14B 74.22B 1.23B 7.53B 2.97B 35.52B 3.09B 3.03B 130B
Net income 47.76M 40.93M 38.09M 35.46M 66.27M 4.3B 71.18M 437M 172M 2.06B 179M 175M 7.55B 64.84M 55.58M 51.72M 48.15M 89.98M 5.84B 96.65M 593M 234M 2.8B 243M 238M 10.25B
Net Debt -280M -240M -223M -208M -388M -25.21B -417M -2.56B -1.01B -12.06B -1.05B -1.03B -44.22B -427M -366M -341M -317M -593M -38.48B -637M -3.91B -1.54B -18.42B -1.6B -1.57B -67.51B
More financial data * Estimated data
Logo Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
Employees
1,778
More about the company
Date Price Change Volume
26-01-09 166.82 $ +0.24% 396,143
26-01-08 166.42 $ -1.56% 664,012
26-01-07 169.05 $ -1.86% 911,443
26-01-06 172.26 $ +1.66% 696,826

Delayed Quote Nasdaq, January 12, 2026 at 04:00 pm EST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
166.82USD
Average target price
190.33USD
Spread / Average Target
+14.10%
Consensus

Quarterly revenue - Rate of surprise